Angiogenesis: the Yin and Yang in intrahepatic cholangiocarcinoma

Abstract

The tumor microenvironment (TME) constitutes a complex structure comprising different cell types and soluble factors that surround the tumor and promote its progression. Primarily for its pivotal role in malignant growth, TME has become a potential therapeutic objective for developing new targeted therapy and a marker for assessing therapeutic response. In intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver malignancy, TME has also gained a central role in understanding the mechanisms underlying tumor progression. In this review, we focused on the role of angiogenic factors and their pathway in iCCA and analyzed possible therapeutic and prognostic implications.

Keywords

Intrahepatic cholangiocarcinoma / angiogenic factors / VEGF / angiopoietins / thrombospondin 1 / endothelins

References

[1] Banales JM,Lamarca A.Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Nat Rev Gastroenterol Hepatol2020;17:557-88. PMCID:PMC7447603

[2] Yamasaki S.Intrahepatic cholangiocarcinoma: macroscopic type and stage classification.J Hepatobiliary Pancreat Surg2003;10:288-91

[3] Krasinskas AM.Cholangiocarcinoma.Surg Pathol Clin2018;11:403-29.

[4] Rodrigues PM,Paiva NA.Pathogenesis of cholangiocarcinoma.Annu Rev Pathol2021;16:433-63

[5] Hucke F,Hucke M.Changing epidemiological trends of hepatobiliary carcinomas in Austria 2010-2018.Cancers2022;14:3093 PMCID:PMC9264900

[6] Turati F,Negri E.Epidemiology of cholangiocarcinoma.Hepatoma Res2022;8:19

[7] Mauro E,Sauri T.New challenges in the management of cholangiocarcinoma: the role of liver transplantation, locoregional therapies, and systemic therapy.Cancers2023;15:1244 PMCID:PMC9953927

[8] Valle J,Palmer DH.ABC-02 Trial InvestigatorsCisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med2010;362:1273-81.

[9] Ohaegbulam KC,Fung A.The multidisciplinary management of cholangiocarcinoma.Cancer2023;129:184-214

[10] Rizvi S.Pathogenesis, diagnosis, and management of cholangiocarcinoma.Gastroenterology2013;145:1215-29 PMCID:PMC3862291

[11] Nakamura H,Totoki Y.Genomic spectra of biliary tract cancer.Nat Genet2015;47:1003-10

[12] Verlingue L,Boige V,Malka D.Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?.Eur J Cancer2017;81:161-73

[13] Anderson NM.The tumor microenvironment.Curr Biol2020;30:R921-5. PMCID:PMC8194051

[14] Lorenzini S,Boulter L.Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver.Gut2010;59:645-54 PMCID:PMC3034133

[15] Sirica AE.Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting.Hepatology2014;59:2397-402 PMCID:PMC3975806

[16] Brivio S,Strazzabosco M.Tumor reactive stroma in cholangiocarcinoma: the fuel behind cancer aggressiveness.World J Hepatol2017;9:455-68 PMCID:PMC5368623

[17] Ferrara N.VEGF and the quest for tumour angiogenesis factors.Nat Rev Cancer2002;2:795-803

[18] Muz B,Azab F.The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy.Hypoxia2015;3:83-92. PMCID:PMC5045092

[19] Morine Y,Utsunomiya T.Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma.Hepatogastroenterology2011;58:1439-44.

[20] Fabris L,Fiorotto R.Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases.Hepatology2006;43:1001-12

[21] Cadamuro M,Brivio S.The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma.Biochim Biophys Acta Mol Basis Dis2018;1864:1435-43 PMCID:PMC6386155

[22] Akkoc Y,Akcay A.Autophagy and Cancer Dormancy.Front Oncol2021;11:627023 PMCID:PMC8017298

[23] Balayan V.Tumor dormancy: biologic and therapeutic implications.World J Oncol2022;13:8-19 PMCID:PMC8913011

[24] Baeriswyl V.The angiogenic switch in carcinogenesis.Semin Cancer Biol2009;19:329-37

[25] Mowers EE,Macleod KF.Autophagy in cancer metastasis.Oncogene2017;36:1619-30 PMCID:PMC5337449

[26] Levine B.Cell biology: autophagy and cancer.Nature2007;446:745-7.

[27] Karakaş D,Ulukaya E.Cancer stem cells: emerging actors in both basic and clinical cancer research.Turk J Biol2014;38:829-38

[28] Sirica AE.The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.Nat Rev Gastroenterol Hepatol2011;9:44-54

[29] Leyva-Illades D,Quinn M.Cholangiocarcinoma pathogenesis: role of the tumor microenvironment.Transl Gastrointest Cancer2012; 1:71-80. PMCID:PMC3448449

[30] Hasita H,Okabe H.Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma.Cancer Sci2010;101:1913-9

[31] Jin MZ.The updated landscape of tumor microenvironment and drug repurposing.Signal Transduct Target Ther2020;5:166 PMCID:PMC7447642

[32] Kawahara N,Taguchi K.Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma.Hepatology1998;28:1512-7.

[33] Roy S,Chakraborty S.Inflammation and progression of cholangiocarcinoma: role of angiogenic and lymphangiogenic mechanisms.Front Med2019;6:293 PMCID:PMC6930194

[34] Zhu AX,Blaszkowsky LS.Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.Lancet Oncol2010;11:48-54

[35] Lubner SJ,Kolesar JL.Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.J Clin Oncol2010;28:3491-7. PMCID:PMC2917213

[36] Guion-Dusserre JF,Vincent J,Ghiringhelli F.FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.World J Gastroenterol2015;21:2096-101 PMCID:PMC4326145

[37] Iyer RV,Groman A.A multicenter phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer.Am J Clin Oncol2018;41:649-55

[38] Bréchon M,Dréanic J.Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers.Invest New Drugs2018;36:156-62

[39] Larsen FO,Diness LV.Efficacy and safety of capecitabine, irinotecan, gemcitabine, and bevacizumab as second-line treatment in advanced biliary tract cancer: a phase II study.Oncology2018;94:19-24

[40] Pei SN,Chen YS.A novel combination of bevacizumab with chemotherapy improves therapeutic effects for advanced biliary tract cancer: a retrospective, observational study.Cancers2021;13:3831 PMCID:PMC8345065

[41] Bengala C,Malavasi N.Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.Br J Cancer2010;102:68-72 PMCID:PMC2813746

[42] Yi JH,Lee J.A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.Eur J Cancer2012;48:196-201

[43] El-Khoueiry AB,Ben-Josef E.SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.Invest New Drugs2012;30:1646-51 PMCID:PMC3490705

[44] Lee JK,O'Reilly EM.A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.Br J Cancer2013;109:915-9 PMCID:PMC3749586

[45] El-Khoueiry AB,Siegel AB.S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.Br J Cancer2014;110:882-7 PMCID:PMC3929880

[46] Moehler M,Schimanski C.Working Group of Internal OncologyGemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.Eur J Cancer2014;50:3125-35

[47] Santoro A,Pressiani T.A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.Ann Oncol2015;26:542-7

[48] Valle JW,Lopes A.Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.Lancet Oncol2015;16:967-78 PMCID:PMC4648082

[49] Dreyer C,Bouattour M.Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy.World J Hepatol2015;7:910-5 PMCID:PMC4411533

[50] Kessler ER,Pitts TM.Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.Invest New Drugs2016;34:176-83. PMCID:PMC4788525

[51] Shroff RT,O'Connor A.The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.Br J Cancer2017;116:1402-7 PMCID:PMC5520097

[52] Sun W,Normolle D.A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.Cancer2019;125:902-9 PMCID:PMC6402964

[53] Kim RD,Poklepovic AS.A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.Cancer2020;126:3464-70. PMCID:PMC7787270

[54] Cousin S,Guegan JP.Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.Eur J Cancer2022;162:161-9

[55] Ding X,Sun W.Sintilimab combined with lenvatinib for advanced intrahepatic cholangiocarcinoma in second-line setting-a multi-center observational study.Front Oncol2022;12:907055 PMCID:PMC9333059

[56] Zhu C,Yang X.Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.Cancer Immunol Immunother2023;72:2949-60 PMCID:PMC10412480

[57] Shi GM,Wu D.Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.Signal Transduct Target Ther2023;8:106 PMCID:PMC10020443

[58] Holmes DI.The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease.Genome Biol2005;6:209 PMCID:PMC551528

[59] Ferrara N,LeCouter J.The biology of VEGF and its receptors.Nat Med2003;9:669-76

[60] Rajabi P,Mokhtari M,Eftekhari M.The role of VEGF in melanoma progression.J Res Med Sci2012;17:534-9

[61] De Paola F,Scarpi E.Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer.Int J Cancer2002;98:228-33.

[62] Niklińska W,Chyczewski L.Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis.Lung Cancer2001;34 Suppl 2:S59-64.

[63] Fabris L,Libbrecht L.Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development.Hepatology2008;47:719-28

[64] Mancino A,Glaser SS.Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor.Dig Liver Dis2009;41:156-63 PMCID:PMC2626155

[65] Hida Y,Fujita M.Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas.Anticancer Res1999;19:2257-60

[66] Möbius C,Aigner T.Evaluation of VEGF a expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma.Eur J Surg Oncol2007;33:1025-9

[67] Yoshikawa D,Iwasaki M.Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.Br J Cancer2008;98:418-25 PMCID:PMC2361442

[68] Cai C,Fu Q.The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.World J Surg Oncol2022;20:40 PMCID:PMC8859901

[69] Calastri MCJ,Tenani GD.Investigating VEGF. miR-145-3p, and miR-101-3p expression in patients with cholangiocarcinoma.Asian Pac J Cancer Prev2022;23:2233-41 PMCID:PMC9727337

[70] Luo X,Huang Z.Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.Oncotarget2017;8:17246-57 PMCID:PMC5370037

[71] Huang MP,Huang B.Apatinib inhibits angiogenesis in intrahepatic cholangiocarcinoma by regulating the vascular endothelial growth factor receptor-2/signal transducer and activator of transcription factor 3/hypoxia inducible factor 1 subunit alpha signaling axis.Pharmacology2021;106:509-19

[72] Peng H,Li J.Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.Oncotarget2016;7:17220-9. PMCID:PMC4941382

[73] Lin G,Wu X.Efficacy and safety of apatinib treatment for patients with advanced intrahepatic cholangiocarcinoma.Cancer Manag Res2020;12:11523-6. PMCID:PMC7666978

[74] Tait CR.Angiopoietins in tumours: the angiogenic switch.J Pathol2004;204:1-10

[75] Zadeh G,Pillo L,Guha A.Role of ang1 and its interaction with VEGF-A in astrocytomas.J Neuropathol Exp Neurol2004;63:978-89.

[76] Moon WS,Kang MJ.Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?.Mod Pathol2003;16:552-7.

[77] Tang D,Yamamoto H.Angiogenesis in cholangiocellular carcinoma: Expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance.Oncol Rep2006;15:525-32.

[78] Voigtländer T,Thamm K.Angiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma.PLoS One2014;9:e97046 PMCID:PMC4019663

[79] Kimawaha P,Junsawang P.Establishment of a potential serum biomarker panel for the diagnosis and prognosis of cholangiocarcinoma using decision tree algorithms.Diagnostics2021;11:589 PMCID:PMC8064492

[80] Atanasov G,Dietel C.Prognostic significance of TIE2-expressing monocytes in hilar cholangiocarcinoma.J Surg Oncol2016;114:91-8.

[81] Atanasov G,Feldbrügge L.Angiogenic miRNAs, the angiopoietin axis and related TIE2-expressing monocytes affect outcomes in cholangiocarcinoma.Oncotarget2018;9:29921-33 PMCID:PMC6057457

[82] Adams JC.Thrombospondins: multifunctional regulators of cell interactions.Annu Rev Cell Dev Biol2001;17:25-51

[83] Aishima S,Sugimachi K.The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.Int J Surg Pathol2002;10:47-56

[84] Carpino G,Di Giamberardino A.Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.J Hepatol2021;75:1377-86

[85] Poon RT,Cheung ST.Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma.Clin Cancer Res2004;10:4150-7.

[86] Ding DY,Zhang JN.Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma.Br J Cancer2023;128:907-17 PMCID:PMC9977883

[87] Bagnato A.The endothelin axis in cancer.Int J Biochem Cell Biol2008;40:1443-51

[88] Nelson J,Battistini B.The endothelin axis: emerging role in cancer.Nat Rev Cancer2003;3:110-6

[89] Eberl L, Bovey R, Juillerat-Jeanneret L. Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells.Br J Cancer2003;88:788-95 PMCID:PMC2376352

[90] Shen W,Li C.Endothelin-A receptor in gastric cancer and enhanced antitumor activity of trastuzumab in combination with the endothelin-A receptor antagonist ZD4054.Ann N Y Acad Sci2019;1448:30-41

[91] Ahn HM,Kim YJ.Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells.Biochem Biophys Res Commun2020;527:568-73

[92] Rosanò L,Bagnato A.Endothelin 1 in cancer: biological implications and therapeutic opportunities.Nat Rev Cancer2013;13:637-51

[93] Salani D,Nicotra MR.Role of endothelin-1 in neovascularization of ovarian carcinoma.Am J Pathol2000;157:1537-47 PMCID:PMC1885720

[94] Fava G,Gaudio E.Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression.Liver Int2009;29:1031-42 PMCID:PMC2706939

[95] Rizzo A.First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: “And Yet It Moves!.Cancer Treat Res Commun2021;27:100335